Phase II evaluation of VP-16-213 (NSC-141540) and cytembena (NSC-104801) in patients with advanced breast cancer

Cancer Treat Rep. 1976 May;60(5):633-5.
No abstract available

Publication types

  • Clinical Trial
  • Randomized Controlled Trial
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Acrylates / therapeutic use*
  • Breast Neoplasms / drug therapy*
  • Drug Therapy, Combination
  • Etoposide / therapeutic use*
  • Female
  • Humans
  • Podophyllotoxin / analogs & derivatives*

Substances

  • Acrylates
  • Etoposide
  • Podophyllotoxin